TTK Healthcare has reported its third quarter financial performance, showing a considerable decline in net profitability compared to the same period last year. The healthcare company's bottom line faced significant pressure during the quarter under review.

Financial Performance Overview

The company's financial results for the third quarter reveal a substantial drop in net profit margins. The year-on-year comparison indicates challenging operating conditions that impacted the company's profitability during this period.

Key Financial Highlights

The third quarter results demonstrate the impact of various factors on TTK Healthcare's financial performance. The company recorded a net profit of ₹10.50 crores during the quarter, marking a significant decrease from the ₹16.70 crores achieved in the corresponding quarter of the previous fiscal year.

This decline of ₹6.20 crores in absolute terms represents a percentage decrease of 37.13% year-on-year. The substantial reduction in net profit indicates that the company faced operational challenges or market conditions that affected its profitability during the reporting period.

Performance Analysis

The year-on-year comparison reveals the extent of the profit decline experienced by TTK Healthcare. The company's ability to maintain its previous year's profitability levels was significantly impacted during the third quarter, as evidenced by the sharp drop in net profit figures.

The financial performance reflects the current business environment and operational dynamics affecting the healthcare sector company during this reporting period.

TTK Healthcare Limited has announced that its board of directors will convene on January 22, 2026, to review and approve the company's unaudited financial results for the third quarter ended December 31, 2025. The meeting notification was issued on January 2, 2026, in compliance with regulatory requirements.

Board Meeting Details

The pharmaceutical company has scheduled the board meeting in accordance with Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The primary agenda involves consideration and approval of the unaudited financial results for Q3FY26.

Trading Window Restrictions

TTK Healthcare Limited has implemented a trading window closure as part of its insider trading prevention measures. The restriction period extends from January 1, 2026, to January 24, 2026, covering both days inclusively. This measure affects all designated persons of the company and their immediate relatives, who have been specifically instructed not to trade in the company's shares during this period.

Regulatory Compliance Framework

The trading window closure follows the company's earlier communication dated December 26, 2025, which outlined the implementation of these restrictions. The measures align with the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct designed to prevent insider trading activities.

The company has formally notified both the BSE Limited and National Stock Exchange of India Limited about the scheduled board meeting and associated trading restrictions. TTK Healthcare Limited trades on BSE with scrip code 507747 and on NSE with scrip code TTKHLTCARE.